These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32903763)

  • 1.
    Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
    Front Immunol; 2020; 11():1620. PubMed ID: 32903763
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
    Front Immunol; 2022; 13():725679. PubMed ID: 35844619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptomic signatures of tumors undergoing T cell attack.
    Gokuldass A; Schina A; Lauss M; Harbst K; Chamberlain CA; Draghi A; Westergaard MCW; Nielsen M; Papp K; Sztupinszki Z; Csabai I; Svane IM; Szallasi Z; Jönsson G; Donia M
    Cancer Immunol Immunother; 2022 Mar; 71(3):553-563. PubMed ID: 34272988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
    Bao R; Stapor D; Luke JJ
    Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors.
    Wu P; Sun W; Zhang H
    Cancer Immunol Immunother; 2022 Mar; 71(3):747-759. PubMed ID: 34398303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
    Yang H; Zhao L; Zhang Y; Li FF
    Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in
    Li Z; Lin J; Zhang L; Li J; Zhang Y; Zhao C; Wang H
    Future Oncol; 2020 Oct; 16(29):2295-2306. PubMed ID: 32639175
    [No Abstract]   [Full Text] [Related]  

  • 12. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
    Cheng L; Wang Y; Qiu L; Chang Y; Lu H; Liu C; Zhang B; Zhou Y; Bai H; Xiong L; Zhong H; Nie W; Han B
    J Transl Med; 2022 May; 20(1):247. PubMed ID: 35642038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
    Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
    Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
    Liu D; Yang X; Wu X
    Front Immunol; 2021; 12():663495. PubMed ID: 34025664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
    Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
    Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.